Grover Sandeep, Avasthi Ajit, Chakravarty Rahul, Dan Amitava, Chakraborty Kaustav, Neogi Rajarshi, Desouza Avinash, Nayak Omkar, Praharaj Samir Kumar, Menon Vikas, Deep Raman, Bathla Manish, Subramanyam Alka A, Nebhinani Naresh, Ghosh Prosenjit, Lakdawala Bhavesh, Bhattacharya Ranjan, Gania AbMajid
Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Asian J Psychiatr. 2021 Mar;57:102549. doi: 10.1016/j.ajp.2021.102549. Epub 2021 Jan 12.
To evaluate the prescription pattern of patients with BD, currently in clinical remission. Additional aim of the study was tocompare the prescription pattern across different study centres.
Prescription of 773 patients, currently in clinical remission, recruited from the outpatient setting of 14 General Hospital Tertiary Care Units of tertiary care centres in the country were evaluated.
Almost all (98.1 %) participants were on medications at the time of assessment. In terms of conventional mood stabilizers, those receiving valproate (44.2 %), out-numbered those receiving lithium (38.9 %). A small proportion (7.4 %) was receiving a combination of both valproate and lithium. About two-third (62.5 %) were receiving at least one antipsychotic medication, with olanzapine (31.7 %) being the most commonly prescribed antipsychotic, followed by quetiapine (11.1 %), and risperidone (9.6 %). About one-third (34.4 %) of the participants were receiving antidepressants, with sertraline (22.6 %) forming bulk of the prescription. Less than half (43.9 %) of the participants were also receiving a benzodiazepine medication at the time of assessment, with chlordiazepoxide (18 %) being the most common agent, followed by clonazepam (14.5 %). There was variation in the prescription patterns across different centres, in terms of monotherapy, polypharmacy, use of preferred conventional mood stabilizers, use of various antipsychotics and antidepressants.
Besides conventional mood stabilizers, about two-third of patients with bipolar disorder received concomitant antipsychotics, one-third received concomitant antidepressants and less than half received benzodiazepines.
评估目前处于临床缓解期的双相情感障碍(BD)患者的用药模式。该研究的另一个目的是比较不同研究中心的用药模式。
对从该国三级医疗中心的14个综合医院三级护理单元门诊招募的773名目前处于临床缓解期的患者的处方进行了评估。
几乎所有(98.1%)参与者在评估时都在服药。在传统心境稳定剂方面,服用丙戊酸盐的患者(44.2%)多于服用锂盐的患者(38.9%)。一小部分(7.4%)患者同时服用丙戊酸盐和锂盐。约三分之二(62.5%)的患者至少服用一种抗精神病药物,其中奥氮平(31.7%)是最常用的抗精神病药物,其次是喹硫平(11.1%)和利培酮(9.6%)。约三分之一(34.4%)的参与者服用抗抑郁药,其中舍曲林(22.6%)占处方的大部分。不到一半(43.9%)的参与者在评估时还服用苯二氮䓬类药物,其中氯氮䓬(18%)是最常用的药物,其次是氯硝西泮(14.5%)。不同中心在单一疗法、联合用药、首选传统心境稳定剂的使用、各种抗精神病药物和抗抑郁药物的使用方面,用药模式存在差异。
除传统心境稳定剂外,约三分之二的双相情感障碍患者同时服用抗精神病药物,三分之一同时服用抗抑郁药物,不到一半服用苯二氮䓬类药物。